The Lancet HCQ study report: A knee-jerker during pandemic?
Bio Spectrum|July 2020
Praised as a potential miracle cure, hundreds of trials got initiated across the globe for HCQ. Scientists started trying the drugs in low and high doses; alone or combined with other drugs in patients with mild or severe disease. But this hope recently got struck by a big blow when a study came along claiming that these antimalarial drugs not only look ineffective but are downright deadly.
Dr Neel Fofaria
The Lancet HCQ study report:  A knee-jerker during pandemic?

The absence of an effective treatment against the coronavirus infection has led clinicians to redirect drugs that are known to be effective for other medical conditions to the treatment of COVID-19. Key among these repurposed therapeutic agents are the antimalarial drug chloroquine (CQ) and its analogue hydroxychloroquine (HCQ), which is used for the treatment of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.

Praised as a potential miracle cure, hundreds of trials got initiated across the globe for HCQ. Scientists started trying the drugs in low and high doses; alone or combined with other drugs in patients with mild or severe disease.

But this hope recently got struck by a big blow when a study came along claiming that these antimalarial drugs not only look ineffective but are downright deadly. This study, published on May 22 in the elite journal The Lancet, was conducted by three researchers- Dr Mandeep R Mehra from Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, US; Frank Ruschitzka from university Heart Center, University Hospital Zurich, Switzerland; and Dr Amit N Patel from Department of Biomedical Engineering, University of Utah, Salt Lake City, US.

They used hospital records procured by an American healthcare analytics company Surgisphere Corporation, established in 2008 by an Indian Sapan Desai, for their study. According to their findings, COVID-19 patients taking CQ or HCQ were associated with an increase in the risk of ventricular arrhythmias and a greater hazard for in-hospital death with COVID-19. The study concluded that these drug regimens should not be used outside of clinical trials and urgent confirmation from randomised clinical trials is needed.

This story is from the July 2020 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the July 2020 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIO SPECTRUMView All
How Tech Innovations Impact Cardiac Care
Bio Spectrum

How Tech Innovations Impact Cardiac Care

Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.

time-read
6 mins  |
September 2021
Mynvax Offers ‘Warm Vaccine' For COVID-19
Bio Spectrum

Mynvax Offers ‘Warm Vaccine' For COVID-19

Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.

time-read
1 min  |
September 2021
Bio Spectrum

“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”

Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;

time-read
4 mins  |
September 2021
Premas Biotech to commercialise VLP vaccine tech against Delta variant
Bio Spectrum

Premas Biotech to commercialise VLP vaccine tech against Delta variant

Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.

time-read
1 min  |
September 2021
Bio Spectrum

SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future

The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!

time-read
4 mins  |
September 2021
Merck launches Pergoveris Pen for fertility treatment in India
Bio Spectrum

Merck launches Pergoveris Pen for fertility treatment in India

Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.

time-read
1 min  |
September 2021
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
Bio Spectrum

GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B

While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.

time-read
10+ mins  |
September 2021
Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray
Bio Spectrum

Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray

Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation

time-read
1 min  |
September 2021
CEPI prioritises Rift Valley fever vax
Bio Spectrum

CEPI prioritises Rift Valley fever vax

Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.

time-read
1 min  |
September 2021
3D printing moulds healthcare innovations
Bio Spectrum

3D printing moulds healthcare innovations

Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.

time-read
7 mins  |
September 2021